Technical Articles

In the antibody drug development field, half-life is a key metric for evaluating the drug-likeness of antibody molecules, and the interaction between FcRn (neonatal Fc receptor) and IgG directly determines the circulatory half-life of antibodies in vivo. Screening and optimizing antibody molecules and rapidly assessing the binding activity between candidate antibodies and FcRn is an unavoidable experimental step in early antibody screening and Fc structure engineering.